Vitamin D3 and Lung Health: What the 2017 BMJ Meta-Analysis Found

Vitamin D3's role in respiratory immunity moved from observational association to evidence-based conclusion with the 2017 Martineau et al. meta-analysis in the British Medical Journal, one of the largest individual-patient-data meta-analyses conducted on any dietary supplement in respiratory health.

The 2017 BMJ Meta-Analysis

Citation: Martineau AR, Jolliffe DA, Hooper RL, et al. "Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data." BMJ, 2017;356:i6583.

Design: Individual participant data (IPD) meta-analysis of randomized controlled trials

Data source: 25 RCTs, 11,321 participants from 14 countries

Outcome: Incidence of acute respiratory tract infection (primary outcome)

Results

Overall, Vitamin D3 supplementation was associated with a 12% reduction in acute respiratory infection incidence (adjusted odds ratio 0.88, 95% CI 0.81–0.96).

Effect modification by baseline Vitamin D status was significant:

• Participants with baseline 25(OH)D levels below 25 nmol/L: 70% reduction in respiratory infection incidence (OR 0.30, p < 0.001)
• Participants with baseline 25(OH)D above 25 nmol/L: 12% reduction

This dose-response pattern by baseline status is mechanistically coherent and rules out a simple placebo interpretation. The protective effect is largest where deficiency is most severe, consistent with a threshold-driven mechanism.

The Cathelicidin Mechanism

The molecular mechanism explaining Vitamin D3's respiratory protective effect centers on cathelicidin (LL-37), a host-defense peptide:

1. Vitamin D3 (cholecalciferol) is metabolized to 25(OH)D (calcidiol) in the liver, then to 1,25(OH)₂D (calcitriol) in the kidney and in local tissue.
2. Calcitriol binds the Vitamin D Receptor (VDR), which is expressed on alveolar macrophages, bronchial epithelial cells, and lung fibroblasts.
3. VDR activation drives transcription of the cathelicidin gene (CAMP). The cathelicidin precursor protein is cleaved to the active peptide LL-37.
4. LL-37 is a cationic amphipathic peptide that disrupts anionic phospholipid bilayers through electrostatic interaction, destroying the cell membranes of bacteria and enveloped viruses in the respiratory tract.

This mechanism is a first-line innate immune defense, it operates before adaptive immune responses (antibodies, T cells) are activated, at the mucosal surface where pathogens first contact respiratory tissue.

Why Supplemental D3 Matters

Vitamin D deficiency is widespread even in populations with regular sun exposure, because UVB-driven cutaneous synthesis is inhibited by sunscreen use, melanin pigmentation, seasonal angle limitations above 35° latitude, and indoor lifestyle. Oral D3 supplementation reliably raises 25(OH)D levels regardless of these factors.

Including D3 in a respiratory supplement formula targets a deficiency-linked component of respiratory susceptibility that is both common and correctable. The threshold effect identified in the Martineau meta-analysis suggests that users with suboptimal D3 status receive the largest benefit, and given deficiency prevalence, this describes a substantial portion of the supplement-using population.

BreathiZen includes Vitamin D3 alongside its botanical respiratory ingredients, providing the cathelicidin-induction mechanism as one layer of the formula's systemic respiratory support. For full context, see the ingredient panel or the complete review.

Disclosure: breathizen.cc earns affiliate commissions from qualifying purchases. Clinical study citations are provided for educational context. BreathiZen is a dietary supplement, not a pharmaceutical. Statements have not been evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease.